Importantly, we demonstrated that SEC61A1 expression was an independent risk factor for OS among AML patients receiving allo-HSCT, suggesting that targeting SEC61A1 may be a valuable strategy for preventing disease relapse after allo-HSCT. The gene discussed is SEC61A1; the disease is acute myeloid leukemia.